Intuitive Surgical Executives Sell Small Amount of Shares Under Planned Transaction

In recent weeks, three executives of Intuitive Surgical, Inc. (Nasdaq: ISRG) sold small amounts of common stock under prearranged Rule 10b5-1 trading plans. On April 28 and 29, board member Amy L. Ladd sold approximately 600 shares at an average price near $470, generating about $290,000 in proceeds. On May 11, General Counsel and Chief Compliance Officer Gary Loeb disposed of 400 shares in the mid-$440 range, realizing roughly $179,000 in cash, though he still holds a stake valued at approximately $2.6 million. From May 18 to 20, Mark Brosius, Senior Vice President of Manufacturing and Supply Chain, sold 18 shares each day over three days (54 shares in total). All transactions represented only a modest portion of each executive’s existing holdings.

On April 21, Intuitive Surgical reported first-quarter 2026 results, posting revenue of $2.7708 billion and net income of $821.5 million—both reflecting double-digit year-over-year growth. The company also raised its full-year forecast for da Vinci procedure volume. With robotic-surgery adoption expanding across the United States and Europe, investors are increasingly focused on the company’s annual revenue guidance and procedure-growth outlook.

Intuitive Surgical is a leader in minimally invasive robotic surgery, supplying its flagship da Vinci Surgical System and the Ion bronchoscopy system to hospitals worldwide. With thousands of systems installed in over 70 countries, the company generates a high proportion of recurring revenue from consumables and services. It is further extending its growth by broadening indications into cardiac and pulmonary procedures.